The utility of immunohistochemistry for providing genetic information on tumors

International Journal of Surgical Pathology

Volumn 21, Issue 5, 2013, Pages 455-475

  Chan, John K C ^a   Ip, Yiu Tung ^b   Cheuk, Wah ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^b TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

chromosomal translocation; gene amplification; gene deletion; gene mutation; immunohistochemistry; molecular genetics; mutation specific antibody; tumors; virus

Indexed keywords

B RAF KINASE; BETA CATENIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ISOCITRATE DEHYDROGENASE 1; MISMATCH REPAIR PROTEIN; NUCLEOPHOSMIN; PROTEIN BCL 6; PROTEIN P53; UVOMORULIN;

ANTIGEN RETRIEVAL; BREAST CARCINOMA; CHROMOSOME TRANSLOCATION; CYTOGENETICS; EPSTEIN BARR VIRUS; FOLLICULAR LYMPHOMA; GENE AMPLIFICATION; GENE DELETION; GENE FUSION; GENE MUTATION; GENE OVEREXPRESSION; GENE PRODUCT; GENE REARRANGEMENT; GENE TRANSLOCATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MERKEL CELL POLYOMAVIRUS; MISSENSE MUTATION; NONHUMAN; PARATHYROID CARCINOMA; PRIORITY JOURNAL; REVIEW; SYNOVIAL SARCOMA; WART VIRUS;

CHROMOSOMAL TRANSLOCATION; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; MUTATION-SPECIFIC ANTIBODY; TUMORS; VIRUS;

HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS;

EID: 84884690754     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896913502529     Document Type: Review

References (117)

1. Demicco EG. Sarcoma diagnosis in the age of molecular pathology. Adv Anat Pathol. 2013 ; 20: 264-274
2. Rodig S, Chan JK Diagnostic Histopathology of Tumors. 4 th ed.Philadelphia, PA: Elsevier Saunders; 2013:1343-1525. Fletcher CD, ed. Philadelphia, PA: Elsevier Saunders ; 2013: 1343-1525.
3. Masir N, Campbell LJ, Goff LK, et al. BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations. Br J Haematol. 2009 ; 144: 716-725
4. Marino-Enriquez A, Wang WL, Roy A, et al. Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol. 2011 ; 35: 135-144
5. Cook JR, Dehner LP, Collins MH, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol. 2001 ; 25: 1364-1371
6. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013 ; 137: 828-860
7. He R, Patel RM, Alkan S, et al. Immunostaining for SYT protein discriminates synovial sarcoma from other soft tissue tumors: analysis of 146 cases. Mod Pathol. 2007 ; 20: 522-528
8. Suurmeijer AJH, de Bruijn D, van Kessel AG, Miettinen MM, et al WHO Classification of Tumours of Soft Tissue and Bone, World Health Organization Classification of Tumours. 4 th ed.Lyon, France: IARC; 2013:213-215. Fletcher CD Bridge JA Hogendoorn PCW Merens F, ed. Lyon, France: IARC ; 2013: 213-215.
9. Terry J, Saito T, Subramanian S, et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol. 2007 ; 31: 240-246
10. Kosemehmetoglu K, Vrana JA, Folpe AL. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol. 2009 ; 22: 872-878
11. Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am J Surg Pathol. 2009 ; 33: 1743-1751
12. Williamson SR, Bunde PJ, Montironi R, et al. Malignant perivascular epithelioid cell neoplasm (PEComa) of the urinary bladder with TFE3 gene rearrangement: clinicopathologic, immunohistochemical, and molecular features. Am J Surg Pathol. In press ;:
13. Argani P, Aulmann S, Illei PB, et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol. 2010 ; 34: 1395-1406
14. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003 ; 27: 750-761
15. Rekhi B, Ingle A, Agarwal M, Puri A, Laskar S, Jambhekar NA. Alveolar soft part sarcoma "revisited": clinicopathological review of 47 cases from a tertiary cancer referral centre, including immunohistochemical expression of TFE3 in 22 cases and 21 other tumours. Pathology. 2012 ; 44: 11-17
16. Tsuji K, Ishikawa Y, Imamura T. Technique for differentiating alveolar soft part sarcoma from other tumors in paraffin-embedded tissue: comparison of immunohistochemistry for TFE3 and CD147 and of reverse transcription polymerase chain reaction for ASPSCR1-TFE3 fusion transcript. Hum Pathol. 2012 ; 43: 356-363
17. Rao Q, Williamson SR, Zhang S, et al. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol. 2013 ; 37: 804-815
18. Green WM, Yonescu R, Morsberger L, et al. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol. 2013 ; 37: 1150-1163
19. Hugh TJ, Dillon SA, O'Dowd G, et al. β-Catenin expression in primary and metastatic colorectal carcinoma. Int J Cancer. 1999 ; 82: 504-511
20. Wang HL, Lu DW, Yerian LM, et al. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol. 2001 ; 25: 1380-1387
21. Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C, et al. Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol. 2005 ; 29: 653-659
22. Hirokawa M, Maekawa M, Kuma S, Miyauchi A. Cribriform-morular variant of papillary thyroid carcinoma: cytological and immunocytochemical findings of 18 cases. Diagn Cytopathol. 2010 ; 38: 890-896
23. Tanaka Y, Kato K, Notohara K, et al. Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. Cancer Res. 2001 ; 61: 8401-8404
24. Bioulac-Sage P, Laumonier H, Laurent C, Zucman-Rossi J, Balabaud C. Hepatocellular adenoma: what is new in 2008. Hepatol Int. 2008 ; 2: 316-321
25. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005 ; 352: 254-266
26. Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009 ; 23: 1731-1743
27. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011 ; 24: 1248-1253
28. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998 ; 29: 551-558
29. Zheng W, Khurana R, Farahmand S, Wang Y, Zhang ZF, Felix JC. p53 Immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol. 1998 ; 22: 1463-1473
30. Mehrad M, Ning G, Chen EY, Mehra KK, Crum CP. A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol. 2010 ; 17: 293-302
31. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncol. 2009 ; 11: 341-347
32. Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep. 2013 ; 13: 345
33. Joseph NM, Phillips J, Dahiya S, et al. Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants. Mod Pathol. 2013 ; 26: 315-326
34. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009 ; 118: 599-601
35. Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol. 2010 ; 34: 1199-1204
36. Kerr DA, Lopez HU, Deshpande V, et al. Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations. Am J Surg Pathol. 2013 ; 37: 787-795
37. Yousem SA. Role of molecular studies in the diagnosis of lung adenocarcinoma. Mod Pathol. 2012 ; 25: S11 - S17
38. Cooper WA, Yu B, Yip PY, et al. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma [published online June 11, 2013]. J Clin Pathol. :
39. Hannah Wen Y, Brogi E, Hasanovic A, et al. Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma [published online April 19, 2013. Mod Pathol. :
40. Jiang G, Fan C, Zhang X, et al. Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer. PLoS One. 2013 ; 8: e59183
41. Fan X, Liu B, Xu H, et al. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples. Hum Pathol. 2013 ; 44: 1499-1507
42. Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009 ; 15: 3023-3028
43. Pakneshan S, Salajegheh A, Smith RA, Lam AK. Clinicopathological relevance of BRAF mutations in human cancer. Pathology. 2013 ; 45: 346-356
44. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011 ; 364: 2305-2315
45. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010 ; 116: 1919-1923
46. MarinCBeauchetACapperD. Detection of BRAF p.V600E mutations in melanoma by immunohistochemistry has a good interobserver reproducibility [May 7, 2013]. Arch Pathol Lab Med. doi:org/10.5858/arpa.2013-0031-OA.
47. Preusser M, Capper D, Berghoff AS, et al. Expression of BRAF V600E mutant protein in epithelial ovarian tumors. Appl Immunohistochem Mol Morphol. 2013 ; 21: 159-164
48. Sinicrope FA, Smyrk TC, Tougeron D, et al. Mutation-specific antibody detects mutant BRAF protein expression in human colon carcinomas. Cancer. In press ;:
49. Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 2012 ; 36: 1796-1800
50. Bosmuller H, Fischer A, Pham DL, et al. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol. 2013 ; 44: 329-335
51. Bullock M, O'Neill C, Chou A, et al. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer. 2012 ; 19: 779-784
52. Busam KJ, Hedvat C, Pulitzer M, von Deimling A, Jungbluth AA. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol. 2013 ; 37: 413-420
53. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013 ; 37: 61-65
54. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I: the utility of immunohistochemistry. J Mol Diagn. 2008 ; 10: 293-300
55. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II: the utility of microsatellite instability testing. J Mol Diagn. 2008 ; 10: 301-307
56. Klarskov L, Holck S, Bernstein I, et al. Challenges in the identification of MSH6-associated colorectal cancer: rectal location, less typical histology, and a subset with retained mismatch repair function. Am J Surg Pathol. 2011 ; 35: 1391-1399
57. Shia J, Stadler Z, Weiser MR, et al. Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?. Am J Surg Pathol. 2011 ; 35: 447-454
58. Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009 ; 33: 1639-1645
59. Garg K, Shih K, Barakat R, Zhou Q, Iasonos A, Soslow RA. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol. 2009 ; 33: 1869-1877
60. Garg K, Leitao MM, Kauff ND, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol. 2009 ; 33: 925-933
61. Jensen KC, Mariappan MR, Putcha GV, et al. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Am J Surg Pathol. 2008 ; 32: 1029-1037
62. Modica I, Soslow RA, Black D, Tornos C, Kauff N, Shia J. Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol. 2007 ; 31: 744-751
63. Chan JK, Wong CS. Loss of E-cadherin is the fundamental defect in diffuse-type gastric carcinoma and infiltrating lobular carcinoma of the breast. Adv Anat Pathol. 2001 ; 8: 165-172
64. Rakha EA, Patel A, Powe DG, et al. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol. 2010 ; 34: 1472-1479
65. Dabbs DJ, Bhargava R, Chivukula M. Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin. Am J Surg Pathol. 2007 ; 31: 427-437
66. Chan JK Diagnostic Histopathology of Tumors. 4 th ed.Philadelphia, PA: Elsevier Saunders; 2013:1177-1272. Fletcher CD, ed. Philadelphia, PA: Elsevier Saunders ; 2013: 1177-1272.
67. Gill AJ, Clarkson A, Gimm O, et al. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol. 2006 ; 30: 1140-1149
68. Hollmann TJ, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol. 2011 ; 35: e47 - e63
69. Tsai CY, Wong TT, Lee YH, et al. Intact INI1 gene region with paradoxical loss of protein expression in AT/RT: implications for a possible novel mechanism associated with absence of INI1 protein immunoreactivity. Am J Surg Pathol. 2012 ; 36: 128-133
70. Haberler C, Laggner U, Slavc I, et al. Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol. 2006 ; 30: 1462-1468
71. Judkins AR, Mauger J, Ht A, Rorke LB, Biegel JA. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol. 2004 ; 28: 644-650
72. Hoot AC, Russo P, Judkins AR, Perlman EJ, Biegel JA. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol. 2004 ; 28: 1485-1491
73. Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol. 2009 ; 33: 542-550
74. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007 ; 131: 18-43
75. Dei Tos AP, Pedeutour F WHO Classification of Tumours of Soft Tissue and Bone, World Health Organization Classification of Tumours. 4 th ed.Lyon, France: IARC; 2013:33-36. Fletcher CD Bridge JA Hogendoorn PCW Merens F, ed. Lyon, France: IARC ; 2013: 33-36.
76. Aleixo PB, Hartmann AA, Menezes IC, Meurer RT, Oliveira AM. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol. 2009 ; 62: 1127-1135
77. Thway K, Flora R, Shah C, Olmos D, Fisher C. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol. 2012 ; 36: 462-469
78. Mejia-Guerrero S, Quejada M, Gokgoz N, et al. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer. 2010 ; 49: 518-525
79. Yoshida A, Ushiku T, Motoi T, et al. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol. 2010 ; 23: 1279-1288
80. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol. 2007 ; 38: 1293-1304
81. van Gorp J, Weiping L, Jacobse K, et al. Epstein-Barr virus in nasal T-cell lymphomas (polymorphic reticulosis/midline malignant reticulosis) in western China. J Pathol. 1994 ; 173: 81-87
82. van Gorp J, Brink A, Oudejans JJ, et al. Expression of Epstein-Barr virus encoded latent genes in nasal T cell lymphomas. J Clin Pathol. 1996 ; 49: 72-76
83. Horenstein MG, Nador RG, Chadburn A, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. Blood. 1997 ; 90: 1186-1191
84. Gulley ML, Glaser SL, Craig FE, et al. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol. 2002 ; 117: 259-267
85. Delsol G, Brousset P, Chittal S, Rigal-Huguet F. Correlation of the expression of Epstein-Barr virus latent membrane protein and in situ hybridization with biotinylated BamHI-W probes in Hodgkin's disease. Am J Pathol. 1992 ; 140: 247-253
86. Loong F, Chan AC, Ho BC, et al. Diffuse large B-cell lymphoma associated with chronic inflammation as an incidental finding and new clinical scenarios. Mod Pathol. 2010 ; 23: 493-501
87. Sarid R, Klepfish A, Schattner A. Virology, pathogenetic mechanisms, and associated diseases of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8). Mayo Clin Proc. 2002 ; 77: 941-949
88. Du MQ, Diss TC, Liu H, et al. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood. 2002 ; 100: 3415-3418
89. Carbone A, Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol. 2008 ; 140: 13-24
90. Cheuk W, Wong KO, Wong CS, Dinkel JE, Ben-Dor D, Chan JK. Immunostaining for human herpesvirus 8 latent nuclear antigen-1 helps distinguish Kaposi sarcoma from its mimickers. Am J Clin Pathol. 2004 ; 121: 335-342
91. Hong A, Davies S, Lee CS. Immunohistochemical detection of the human herpes virus 8 (HHV8) latent nuclear antigen-1 in Kaposi's sarcoma. Pathology. 2003 ; 35: 448-450
92. Patel RM, Goldblum JR, Hsi ED. Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcoma. Mod Pathol. 2004 ; 17: 456-460
93. Lewis JS, Thorstad WL, Chernock RD, et al. p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol. 2010 ; 34: 1088-1096
94. Bishop JA, Ma XJ, Wang H, et al. Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol. 2012 ; 36: 1874-1882
95. Rabban JT, Soslow RA, Zaloudek CZ, et al Diagnostic Immunohistochemistry: Theranostic and Genomic Applications. 3 rd ed.Philadelphia, PA: Elsevier Saunders; 2012:690-762. Dabbs DJ, ed. Philadelphia, PA: Elsevier Saunders ; 2012: 690-762.
96. Jordan RC, Lingen MW, Perez-Ordonez B, et al. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol. 2012 ; 36: 945-954
97. Yildiz IZ, Usubutun A, Firat P, Ayhan A, Kucukali T. Efficiency of immunohistochemical p16 expression and HPV typing in cervical squamous intraepithelial lesion grading and review of the p16 literature. Pathol Res Pract. 2007 ; 203: 445-449
98. Benevolo M, Mottolese M, Marandino F, et al. Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol. 2006 ; 19: 384-391
99. Lingen MW, Xiao W, Schmitt A, et al. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol. 2013 ; 49: 1-8
100. Bussu F, Sali M, Gallus R, et al. HPV infection in squamous cell carcinomas arising from different mucosal sites of the head and neck region. Is p16 immunohistochemistry a reliable surrogate marker?. Br J Cancer. 2013 ; 108: 1157-1162
101. Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol. 2007 ; 26: 328-333
102. Yemelyanova A, Ji H, Shih Ie M, Wang TL, Wu LS, Ronnett BM. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol. 2009 ; 33: 1504-1514
103. Phillips V, Kelly P, McCluggage WG. Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma. Int J Gynecol Pathol. 2009 ; 28: 179-186
104. Santos M, Landolfi S, Olivella A, et al. p16 overexpression identifies HPV-positive vulvar squamous cell carcinomas. Am J Surg Pathol. 2006 ; 30: 1347-1356
105. Klaes R, Benner A, Friedrich T, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2002 ; 26: 1389-1399
106. O'Neill CJ, McCluggage WG. p16 Expression in the female genital tract and its value in diagnosis. Adv Anat Pathol. 2006 ; 13: 8-15
107. Kalof AN, Evans MF, Simmons-Arnold L, Beatty BG, Cooper K. p16INK4A immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia. Am J Surg Pathol. 2005 ; 29: 674-679
108. Lewis JS, Chernock RD, Ma XJ, et al. Partial p16 staining in oropharyngeal squamous cell carcinoma: extent and pattern correlate with human papillomavirus RNA status. Mod Pathol. 2012 ; 25: 1212-1220
109. El-Naggar AK, Westra WH. p16 Expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck. 2012 ; 34: 459-461
110. Bishop JA, Ogawa T, Chang X, et al. HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Am J Surg Pathol. 2012 ; 36: 142-148
111. Spurgeon ME, Lambert PF. Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential. Virology. 2013 ; 435: 118-130
112. Martin B, Poblet E, Rios JJ, et al. Merkel cell carcinoma with divergent differentiation: histopathological and immunohistochemical study of 15 cases with PCR analysis for Merkel cell polyomavirus. Histopathology. 2013 ; 62: 711-722
113. Busam KJ, Jungbluth AA, Rekthman N, et al. Merkel cell polyomavirus expression in Merkel cell carcinomas and its absence in combined tumors and pulmonary neuroendocrine carcinomas. Am J Surg Pathol. 2009 ; 33: 1378-1385
114. Chun SM, Yun SJ, Lee SC, Won YH, Lee JB. Merkel cell polyomavirus is frequently detected in Korean patients with Merkel cell carcinoma. Ann Dermatol. 2013 ; 25: 203-207
115. Coursaget P, Samimi M, Nicol JT, Gardair C, Touze A. Human Merkel cell polyomavirus: virological background and clinical implications. APMIS. 2013 ; 121: 755-769
116. Duncavage EJ, Le BM, Wang D, Pfeifer JD. Merkel cell polyomavirus: a specific marker for Merkel cell carcinoma in histologically similar tumors. Am J Surg Pathol. 2009 ; 33: 1771-1777
117. Hattori T, Takeuchi Y, Takenouchi T, et al. The prevalence of Merkel cell polyomavirus in Japanese patients with Merkel cell carcinoma. J Dermatol Sci. 2013 ; 70: 99-107